Opinion

Video

Overview of Efficacy and Safety Data for Current CLL Treatment Options

A general overview of efficacy and safety data for current treatment options for patients with chronic lymphocytic leukemia.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
fda sign.
July 1st 2025

Therapies Which Received FDA Approval in July: What Patients Should Know

Ryan Scott
Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology indications and cancer types.
A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More
January 22nd 2024

A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More

Alex Biese Brielle Benyon
We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.
Image of blood cells.
June 26th 2025

June Blood Cancer Highlights: Top 5 Updates Patients Should Know

Ryan Scott
June brought major blood cancer updates, and CURE is sharing the latest in myelofibrosis treatment and FDA breakthroughs, as well as survivorship news.
CURE Talks Cancer podcast
December 31st 2020

The Treatment Journey of a Patient with CLL

Kristie L. Kahl
In this episode of the “CURE Talks Cancer” podcast, we spoke with Mark Hoffman, a patient with chronic lymphocytic leukemia, about his diagnosis and treatment journey.
FDA approves new Brukinsa tablet for five blood cancers: © stock.adobe.com.
June 12th 2025

FDA Approves Brukinsa Tablet For Various Blood Cancers

Spencer Feldman
FDA approves new Brukinsa tablet for five blood cancers, offering simpler dosing with the same safety and effectiveness as capsules.
After surviving prostate cancer, Andy Winnegar received a diagnosis of chronic lymphocytic leukemia (CLL) in 2021. Catch up on Andy's blogs here!
May 28th 2025

Rebuilding Resilience: Navigating Aging and Exercise After CLL

Andy Winnegar
After running the Boston Marathon at 67, I faced new limits from aging and chronic lymphocytic leukemia — but I’ve found ways to stay strong and resilient.